Harmony Biosciences Holdings Inc Ordinary Shares HRMY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
-
Harmony Biosciences Gets FDA Approval for Cataplexy Treatment for Children With Narcolepsy
-
11 fast-growing small-cap stocks that could get a boost from the Fed's next move
-
11 fast-growing small-cap stocks that could -2-
Trading Information
- Previous Close Price
- $39.57
- Day Range
- $39.25–40.62
- 52-Week Range
- $25.52–43.49
- Bid/Ask
- $38.30 / $42.22
- Shares Outstanding
- 58.24M
- Market Cap
- $2.31B
- Volume/Avg
- 916,733 / 891,269
Key Statistics
- Price/Earnings (Normalized)
- 11.37
- Price/Sales
- 2.42
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 293
Valuation
|
Metric
|
HRMY
|
|---|---|
Price/Earnings (Normalized) | 11.37 |
Price/Book Value | 2.30 |
Price/Sales | 2.42 |
Price/Cash Flow | 7.84 |
Price/Earnings
HRMY
Financial Strength
|
Metric
|
HRMY
|
|---|---|
Quick Ratio | 3.33 |
Current Ratio | 3.48 |
Interest Coverage | 17.09 |
Quick Ratio
HRMY
Profitability
|
Metric
|
HRMY
|
|---|---|
Return on Assets (Normalized) | 17.01% |
Return on Equity (Normalized) | 24.16% |
Return on Invested Capital (Normalized) | 19.58% |
Return on Assets
HRMY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%pT%Jt | LOCK|phj%Z | $128B | |||
| Moderna Inc
MRNA
| LOCK|t!@RBWJ | LOCK|k?& | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|SQ<>!% | LOCK|%!B@^ | $76B | |||
| argenx SE ADR
ARGX
| LOCK|b^T?^L | LOCK|@@< | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$#t@$^G | LOCK|?< | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|JTM&p& | LOCK|HRHw | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!r>d#QD | LOCK|$DYj> | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|Rbgp@$@ | LOCK|NkG | $24B | |||
| Incyte Corp
INCY
| LOCK|&t>P&G | LOCK|P^p | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|TkgDtR< | LOCK|%S% | $15B |
United States